Metagenomi reports $160.8M cash, MGX-001 on track for IND in 4Q 2026

Metagenomi Therapeutics, Inc.

Cash, equivalents and marketable securities $160.8M as of Dec 31, 2025; runway through 4Q 2027.
R&D expenses $94.4M in FY2025 (down 13.6% from FY2024); G&A $26.8M (down 16.3% from $32.0M).
MGX-001 hemophilia A pre-IND meeting completed; IND filing expected 4Q 2026, clinical trials in 2027.
Preclinical NHP data showed curative FVIII levels; in vivo proof-of-concept for Antithrombin deficiency also achieved.
Corporate name changed to Metagenomi Therapeutics; Ionis collaboration advancing APOC3 target in cardiometabolic indications.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Metagenomi Therapeutics, Inc. reported financial results for the full year ended December 31, 2025.

Period: the full year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 5, 2026, Metagenomi Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2025 and additional business updates.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Metagenomi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-093943

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.